Measurable residual disease testing for personalized treatment of acute myeloid leukemia

Forskningsoutput: TidskriftsbidragÖversiktsartikel

Abstract

This review summarizes – with the practicing hematologist in mind – the methods used to determine measurable residual disease (MRD) in everyday practice with some future perspectives, and the current knowledge about the prognostic impact of MRD on outcome in acute myeloid leukemia (AML), excluding acute promyelocytic leukemia. Possible implications for choice of MRD method, timing of MRD monitoring, and guidance of therapy are discussed in general and in some detail for certain types of leukemia with specific molecular markers to monitor, including core binding factor (CBF)-leukemias and NPM1-mutated leukemias.

Detaljer

Författare
Enheter & grupper
Externa organisationer
  • Skåne University Hospital
  • Halmstad County Hospital
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Hematologi

Nyckelord

Originalspråkengelska
Sidor (från-till)337-351
TidskriftAPMIS
Volym127
Utgåva nummer5
Tidigt onlinedatum2019 mar 28
StatusPublished - 2019
PublikationskategoriForskning
Peer review utfördJa